Compositions and methods for treating depression
Disclosed are a novel combination of specific therapeutics selected from S-adenosyl methionine or a salt thereof, folic acid or a metabolite or salt thereof, and one or more omega-3 fatty acids or salts thereof, useful for a variety of conditions, as discussed herein. Methods of treatment include the treatment of neuropsychiatric conditions, such as depression.
1. A method for treating depression in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of:
S-adenosyl methionine or a salt thereof, wherein S-adenosyl methionine or a salt thereof provided in a range of between about 800 mg to about 1600 mg, inclusive;
methyl folate or a salt thereof, wherein methyl folate of a salt thereof is provided in a range between about 5 mg to about 20 mg, inclusive; and
one or more omega-3 fatty acids or salts thereof, wherein the omega-3 fatty acids or salts thereof are provided in a range of between about 500 mg to about 1800 mg, inclusive,
wherein the one or more omega-3 fatty acids or salts thereof comprises at least 60% eicosapentaenoic acid (EPA) or salt thereof.
2. The method of claim 1 , wherein the method comprises administering S-adenosyl methionine or a salt thereof and methyl folate or a salt thereof together in the same composition, and administering the one or more omega-3 fatty acids or salts thereof in a separate composition.
3. The method of claim 1 , wherein the method comprises administering each of S-adenosyl methionine or a salt thereof, methyl folate or a salt thereof, and one or more omega-3 fatty acids or salts thereof in separate compositions.
4. The method of claim 1 , wherein the step of administering is orally administering.
5. The method of claim 1 , wherein the omega-3 fatty acids or salts thereof is provided in a range of between about 800 mg to about 1600 mg, inclusive.
6. The method of claim 1 , wherein the one or more omega-3 fatty acids or salts thereof comprises a combination of eicosapentaenoic acid (EPA) or salt thereof and docosahexaenoic acid (DHA) or salt thereof.
7. The method of claim 1 , wherein the subject is a mammal.
8. The method of claim 7 , wherein the mammal is a human subject.
9. The method of claim 1 , wherein the depression is Major Depressive Disorder.
10. The method of claim 1 , wherein the subject s receiving or has received a prescription anti-depressant.
11. The method of claim 10 , wherein the prescription anti-depressant is selected from the group consisting of selective serotonin reuptake inhibitors (SSRIs), serotonin and dopamine reuptake inhibitors (SDRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), serotonin-noradrenaline-dopamine reuptake inhibitors (SNDRIs), norepinephrine-dopamine reuptake inhibitors (NDRIs), norepinephrine (noradrenaline) reuptake inhibitors (NRIs), monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake enhancers (SSREs), melatonergic agonists, tryptamines, tricyclic anti-depressants, and atypical anti-depressants.